775 related articles for article (PubMed ID: 18604487)
1. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
2. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
[TBL] [Abstract][Full Text] [Related]
3. Treatment and long-term follow-up of patients with stage II to III idiopathic membranous nephropathy.
Polenakovik MH; Grcevska L
Am J Kidney Dis; 1999 Nov; 34(5):911-7. PubMed ID: 10561149
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report.
Sirimongkolrat T; Premasathian N; Vongwiwatana A; Limsrichamrern S; Cheunsuchon B; Vasuvattakul S
Transplant Proc; 2008 Sep; 40(7):2440-1. PubMed ID: 18790261
[TBL] [Abstract][Full Text] [Related]
6. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic membranous nephropathy: diagnosis and treatment.
Fervenza FC; Sethi S; Specks U
Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
9. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A treatment for idiopathic membranous nephropathy.
Yao X; Chen H; Wang Q; Tang Z; Hu W; Yin G; Liu Z; Li L
Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.
Ponticelli C; Zucchelli P; Passerini P; Cagnoli L; Cesana B; Pozzi C; Pasquali S; Imbasciati E; Grassi C; Redaelli B
N Engl J Med; 1989 Jan; 320(1):8-13. PubMed ID: 2642605
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G
Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125
[TBL] [Abstract][Full Text] [Related]
17. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects.
Terrier B; Delmas Y; Hummel A; Presne C; Glowacki F; Knebelmann B; Combe C; Lesavre P; Maillard N; Noël LH; Patey-Mariaud de Serre N; Nusbaum S; Radford I; Buzyn A; Fakhouri F
Nephrol Dial Transplant; 2007 May; 22(5):1369-76. PubMed ID: 17255123
[TBL] [Abstract][Full Text] [Related]
18. The therapy of idiopathic membranous glomerulonephritis.
Glassock RJ
Semin Nephrol; 1991 Mar; 11(2):138-47. PubMed ID: 2034923
[TBL] [Abstract][Full Text] [Related]
19. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab.
Westphal S; Hansson S; Mjörnstedt L; Mölne J; Swerkersson S; Friman S
Transplant Proc; 2006 Oct; 38(8):2659-60. PubMed ID: 17098031
[TBL] [Abstract][Full Text] [Related]
20. Membranous nephropathy with crescents: a series of 19 cases.
Rodriguez EF; Nasr SH; Larsen CP; Sethi S; Fidler ME; Cornell LD
Am J Kidney Dis; 2014 Jul; 64(1):66-73. PubMed ID: 24709471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
